FDA Clears Ameluz for Superficial Basal Cell Carcinoma Treatment

The FDA has approved Ameluz topical gel, combined with BF-RhodoLED lamp photodynamic therapy, for treating superficial basal cell carcinoma in adults. This marks the first FDA-sanctioned PDT drug for skin cancer, expanding its use beyond actinic keratoses and offering a new therapeutic option for patients.